Recent News

• 02.09.2026 - Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
• 02.04.2026 - Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
• 01.28.2026 - Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
• 01.25.2026 - FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review
• 01.12.2026 - Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
• 01.06.2026 - Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China
• 12.22.2025 - The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
• 12.08.2025 - “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List
• 12.05.2025 - Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
• 12.03.2025 - Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025

Recent Filings

• 02.09.2026 - 144 Report of proposed sale of securities
• 02.06.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.06.2026 - EX-99.1 EX-99.1
• 02.06.2026 - 8-K Current report
• 02.05.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.02.2026 - 144 Report of proposed sale of securities
• 01.14.2026 - 8-K Current report
• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities